A small randomized crossover trial indicates that treatment with empagliflozin in people with type 2 diabetes and heart failure already using a loop diuretic results in increased urine output without sodium loss.
Both moderate and high alcohol consumption are independently associated with hypertension in people with type 2 diabetes and cardiovascular disease, and the risk rises with increasing consumption, ACCORD study data suggest.
Type 2 diabetes and weight loss are independently associated with an increased risk for pancreatic cancer, and this risk is further elevated when weight loss occurs together with recent-onset diabetes, according to results from a cohort study.
The strongest predictor of type 2 diabetes remission is weight loss, with other variables only modestly associated with outcome and insufficient to identify people unsuitable for attempting this goal, shows a post-hoc analysis of DiRECT data.
The risk for someone with type 2 diabetes experiencing a cardiovascular disease event increases by 21% for every 1% increase in their usual glycated hemoglobin level above 7.0%, study findings suggest.
Older patients and those with cardiovascular disease are most likely to have an increased risk for lower limb amputation when newly prescribed canagliflozin, relative to a GLP-1 receptor agonist, research shows.
The primary findings of the DAPA-CKD trial show that dapagliflozin significantly slows decline in kidney function in patients with chronic kidney disease irrespective of whether they have type 2 diabetes.
The EMPEROR-Reduced investigators have revealed that empagliflozin provides significant protection against cardiovascular death and heart failure in patients with heart failure and reduced ejection fraction, with or without diabetes.
Children with type 1 diabetes who use the Tandem Control-IQ hybrid closed-loop insulin delivery system spend more time with their blood glucose levels in the target range than those using a sensor-augmented insulin pump, show findings from the iDCL trial.
A prospective study has revealed that greater fasting glucose variability during young adulthood is independently associated with increased risk for coronary artery calcification progression in middle age.
A collaborative care intervention delivered at urban diabetes clinics improves depressive symptoms and cardiometabolic outcomes among people with comorbid diabetes and depression in India, shows the INDEPENDENT trial.